Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Medivir AB (Nasdaq Stockholm: MVIR) announced today that it had entered into a license agreement with Ubiquigent Limited (Ubiquigent) for Medivir's...
The shareholders of Medivir AB, reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the extraordinary...
The Board of Directors in Medivir AB (publ) ("Medivir" or the "Company") has decided to summon an extraordinary general meeting on 11 March 2021 to...
Resolution regarding reduction of the share capital without cancellation of shares The extraordinary general meeting in Medivir Aktiebolag (publ) on...
Medivir AB (Nasdaq Stockholm: MVIR) today announces that a presentation entitled "Phase I study of the novel pro-drug MIV-818 in patients with...
Medivir AB (publ) (Nasdaq Stockholm: MVIR) today announced that it has entered into an exclusive licensing agreement, through which IGM Biosciences,...
Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Company") has renegotiated its agreement with TetraLogic...
Continued focus on MIV-818 July – September Significant events during the quarter In July, a research collaboration was initiated with the Drug...
Medivir AB (Nasdaq Stockholm: MVIR) announced today it has appointed Dr. Tom Morris as interim Chief Medical Officer effective October 5, 2020. Dr....
April - June Significant events during the quarter Following the positive opinion given by the European Medicines Agency (EMA), the European...
Medivir AB (Nasdaq Stockholm: MVIR) announced today that Dr. Yilmaz Mahshid will assume his position as CEO on September 14, 2020. Uli Hacksell, who...
Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered a research collaboration with the Drug Discovery and Development Platform...
Medivir AB (Nasdaq Stockholm: MVIR) today announced that the European Commission, in accordance with the opinion from the European Medicines Agency...
Medivir AB (Nasdaq Stockholm: MVIR) today announced that its Board of Directors has appointed Yilmaz Mahshid as the new CEO of the company. Yilmaz...
Medivir AB (Nasdaq Stockholm: MVIR) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to...
Approval of profit and loss accounts and balance sheets, and discharge from liability of the board members and the managing director The annual...
Positive results for MIV-818 and continued tempo in business development January - March Significant events during the quarter Data from the phase Ia ...
Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has received positive opinion from the Committee for Orphan Medicinal Products on orphan...
Medivir AB (Nasdaq Stockholm: MVIR) announces that Linda Basse, Chief Medical Officer at Medivir will leave the company on September 30, 2020. A...
Medivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2019 now is available at the company's website: www.medivir.com. The...
The shareholders of Medivir AB are hereby summoned to the annual general meeting on Tuesday 5 May 2020 at 2 p.m. at Tändstickspalatset, Västra...
Medivir AB (Nasdaq Stockholm: MVIR) today announced that it has entered into a license agreement with US biotech company Tango Therapeutics for one...
Medivir AB (Nasdaq Stockholm: MVIR) today announced that the first patient with advanced liver cancer has been dosed in the phase Ib study of MIV-818....
Medivir AB (Nasdaq Stockholm: MVIR) announces that new data from the completed phase Ia study with MIV-818 will be presented at the R&D day hosted by ...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.